中国实用外科杂志2024，Vol.44Issue(10)：1090-1094,5.DOI:10.19538/j.cjps.issn1005-2208.2024.10.02
胃癌新辅助治疗靶点的研究进展和发展方向
Research progress and development of neoadjuvant therapy targets in gastric cancer
摘要
Abstract
As an important component of gastric cancer treatment,neoadjuvant therapy has been increasingly proven to be effective and safe in reducing tumor size,improving surgical resection rates,and enhancing patient survival through clinical research data represented by the RESOLVE study.The in-depth study of targets such as human epidermal growth factor receptor-2(HER2),vascular endothelial growth factor receptor(VEGF)and its receptor(VEGFR),FGFR2,Claudin 18.2,and programmed death receptor-1(PD-1)and its ligand(PD-L1)has brought new treatment options for patients.In particular,HER2-targeted drugs and immune checkpoint inhibitors have shown encouraging efficacy in clinical trials,bringing hope for improving patient survival and prognosis.However,this field still faces many challenges,including validation of therapeutic efficacy and safety,screening of biomarkers,optimization of multi-target combination strategies,and development of treatment response evaluation criteria.In the future,neoadjuvant therapy for gastric cancer will emphasize the importance of multidisciplinary cooperation,pay more attention to individualization and precision,optimize treatment plans,and further improve treatment effectiveness and patient quality of life.关键词
胃癌/新辅助治疗/分子亚型/生物标记物/免疫治疗/靶向治疗Key words
gastric cancer/neoadjuvant therapy/molecular subtypes/biomarkers/immunotherapy/targeted therapy分类
医药卫生引用本文复制引用
王振宁..胃癌新辅助治疗靶点的研究进展和发展方向[J].中国实用外科杂志,2024,44(10):1090-1094,5.基金项目
国家科技重大专项(No.2023ZD0501500) （No.2023ZD0501500）
国家自然科学基金项目(No.U23A20457) （No.U23A20457）
